File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: Presence of an in-situ component predicts reduced tumor aggressiveness in luminal subtype of invasive breast cancer

TitlePresence of an in-situ component predicts reduced tumor aggressiveness in luminal subtype of invasive breast cancer
Authors
Issue Date2011
PublisherChurchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/breast
Citation
The 12th International Conference Primary Therapy of Early Breast Cancer, St.Gallen, Switzerland, 15-19 March 2011. In The Breast, 2011, v. 20, suppl. 1, p. S39, article no. P182 How to Cite?
AbstractGOALS: We have previously shown that primary breast invasive ductal carcinoma co-existing with ductal-carcinoma-in-situ (IDC-DCIS) is characterized by lower proliferation rate and metastatic propensity than sizematched pure IDC, especially if the ratio of DCIS to IDC size is high. On the other hand, IDC-DCIS is more often ER-positive, PR-positive and/or HER2-positive than is pure IDC. This analysis aims to clarify whether the presence of co-existing DCIS in IDC affects tumor aggressiveness in various biological subtypes of breast cancer respectively. METHODS: Tumor data obtained from 1355 consecutive female patients undergoing upfront surgery for primary breast cancer were analyzed retrospectively; 196 patients with pure DCIS were excluded. Based on evidence that immunohistochemistry (IHC) provides a reasonable approximation of molecular phenotypes, the tumor samples were divided into 4 groups: (i) luminal A (ER and/or PR-positive, HER2-negative, Ki67_12), (ii) luminal B (ER and/or PR-positive, HER2-negative, Ki67 > 12), (iii) HER2 (HER2-positive) and (iv) basal-like (triple-negative) disease. Ki67 expression and nodal involvement of IDC with or without DCIS in these groups were compared. RESULTS: The number of patients with luminal A, luminal B, HER2 and basal-like breast cancer were 458, 315, 247 and 128 respectively. Ki-67 was lower in IDC-DCIS than in size-adjusted pure IDC of both luminal A and luminal B subtypes (p = 0.15 and <0.005 respectively). Pure IDC of these biological subtypes were also associated with more advanced lymph node status as compared to IDC-DCIS, although not statistically significant. In HER2 or basal-like tumors, there were no significant difference between pure IDC and IDC-DCIS. CONCLUSION: The presence of co-existing DCIS in IDC predicts lower biological aggressiveness in luminal cancers but not in the conventionally more aggressive HER2-positive and triple-negative subtypes.
DescriptionPoster Session 1 - Predictive and prognostic factors
Persistent Identifierhttp://hdl.handle.net/10722/136109
ISSN
2015 Impact Factor: 2.74
2015 SCImago Journal Rankings: 1.346

 

DC FieldValueLanguage
dc.contributor.authorWong, Hen_US
dc.contributor.authorLeung, RCYen_US
dc.contributor.authorLau, Sen_US
dc.contributor.authorChiu, Jen_US
dc.contributor.authorCheung, Pen_US
dc.contributor.authorWong, Ten_US
dc.contributor.authorLiang, Ren_US
dc.contributor.authorEpstein, Ren_US
dc.contributor.authorYau, Ten_US
dc.date.accessioned2011-07-27T02:02:58Z-
dc.date.available2011-07-27T02:02:58Z-
dc.date.issued2011en_US
dc.identifier.citationThe 12th International Conference Primary Therapy of Early Breast Cancer, St.Gallen, Switzerland, 15-19 March 2011. In The Breast, 2011, v. 20, suppl. 1, p. S39, article no. P182en_US
dc.identifier.issn0960-9776-
dc.identifier.urihttp://hdl.handle.net/10722/136109-
dc.descriptionPoster Session 1 - Predictive and prognostic factors-
dc.description.abstractGOALS: We have previously shown that primary breast invasive ductal carcinoma co-existing with ductal-carcinoma-in-situ (IDC-DCIS) is characterized by lower proliferation rate and metastatic propensity than sizematched pure IDC, especially if the ratio of DCIS to IDC size is high. On the other hand, IDC-DCIS is more often ER-positive, PR-positive and/or HER2-positive than is pure IDC. This analysis aims to clarify whether the presence of co-existing DCIS in IDC affects tumor aggressiveness in various biological subtypes of breast cancer respectively. METHODS: Tumor data obtained from 1355 consecutive female patients undergoing upfront surgery for primary breast cancer were analyzed retrospectively; 196 patients with pure DCIS were excluded. Based on evidence that immunohistochemistry (IHC) provides a reasonable approximation of molecular phenotypes, the tumor samples were divided into 4 groups: (i) luminal A (ER and/or PR-positive, HER2-negative, Ki67_12), (ii) luminal B (ER and/or PR-positive, HER2-negative, Ki67 > 12), (iii) HER2 (HER2-positive) and (iv) basal-like (triple-negative) disease. Ki67 expression and nodal involvement of IDC with or without DCIS in these groups were compared. RESULTS: The number of patients with luminal A, luminal B, HER2 and basal-like breast cancer were 458, 315, 247 and 128 respectively. Ki-67 was lower in IDC-DCIS than in size-adjusted pure IDC of both luminal A and luminal B subtypes (p = 0.15 and <0.005 respectively). Pure IDC of these biological subtypes were also associated with more advanced lymph node status as compared to IDC-DCIS, although not statistically significant. In HER2 or basal-like tumors, there were no significant difference between pure IDC and IDC-DCIS. CONCLUSION: The presence of co-existing DCIS in IDC predicts lower biological aggressiveness in luminal cancers but not in the conventionally more aggressive HER2-positive and triple-negative subtypes.-
dc.languageengen_US
dc.publisherChurchill Livingstone. The Journal's web site is located at http://www.elsevier.com/locate/breast-
dc.relation.ispartofThe Breasten_US
dc.titlePresence of an in-situ component predicts reduced tumor aggressiveness in luminal subtype of invasive breast canceren_US
dc.typeConference_Paperen_US
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0960-9776&volume=20&issue=suppl. 1&spage=S39, article no. P182&epage=&date=2011&atitle=Presence+of+an+in-situ+component+predicts+reduced+tumor+aggressiveness+in+luminal+subtype+of+invasive+breast+cancer-
dc.identifier.emailLeung, RCY: rolandleung2003@yahoo.comen_US
dc.identifier.emailChiu, J: jfchiu@hkucc.hku.hk-
dc.identifier.emailYau, T: tyaucc@hku.hk-
dc.identifier.authorityYau, T=rp01466en_US
dc.identifier.hkuros189002en_US
dc.identifier.hkuros198396-
dc.identifier.volume20en_US
dc.identifier.issuesuppl. 1en_US
dc.identifier.spageS39, article no. P182en_US
dc.identifier.epageS39, article no. P182en_US
dc.description.otherThe 12nd International Conference Primary Therapy of Early Breast Cancer, St.Gallen, Switzerland, 15-19 March 2011. In The Breast, 2011, v. 20, suppl. 1, p. S39, article no. P182-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats